Stocks
CalciMedica, Inc.CALC
NASDAQHealthcareBiotechnology$1.23
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies targeting calcium release-activated calcium (CRAC) channels for inflammatory and autoimmune diseases. Its lead candidate, Auxora, is in Phase 2/3 trials for acute pancreatitis and other indications, making it a focus for investors tracking early-stage inflammation treatments.
52W Range: $1.00-$36.00
Congressional Interest in CalciMedica, Inc. (CALC)
No congressional trades have been disclosed for CalciMedica, Inc. (CALC) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CALC?
No congressional trades found for this stock.